- |||||||||| zeluvalimab (AMG 404) / Amgen, etevritamab (AMG 596) / Amgen
Trial completion, Combination therapy, Monotherapy: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov) - Oct 5, 2021
P1, N=30, Completed,
Together, these data show a compelling preclinical efficacy and safety profile of AMG 596, supporting its development as a novel immune therapy for treatment of GBM. Active, not recruiting --> Completed
- |||||||||| zeluvalimab (AMG 404) / Amgen, etevritamab (AMG 596) / Amgen
Trial primary completion date, Combination therapy, Monotherapy: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov) - Aug 18, 2021
P1, N=30, Active, not recruiting,
Active, not recruiting --> Completed Trial primary completion date: Dec 2021 --> Jul 2021
- |||||||||| zeluvalimab (AMG 404) / Amgen, etevritamab (AMG 596) / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov) - Dec 11, 2020
P1, N=30, Active, not recruiting,
Trial primary completion date: Dec 2021 --> Jul 2021 Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021
- |||||||||| zeluvalimab (AMG 404) / Amgen, etevritamab (AMG 596) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov) - Jul 8, 2020
P1, N=30, Active, not recruiting,
Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021 Recruiting --> Active, not recruiting | N=200 --> 30 | Trial completion date: Sep 2024 --> Jun 2021 | Trial primary completion date: Feb 2024 --> Mar 2021
- |||||||||| zeluvalimab (AMG 404) / Amgen, etevritamab (AMG 596) / Amgen
Enrollment change, Trial primary completion date, Combination therapy, Monotherapy: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov) - Feb 23, 2020
P1, N=200, Recruiting,
Recruiting --> Active, not recruiting | N=200 --> 30 | Trial completion date: Sep 2024 --> Jun 2021 | Trial primary completion date: Feb 2024 --> Mar 2021 N=82 --> 200 | Trial primary completion date: Aug 2024 --> Feb 2024
- |||||||||| zeluvalimab (AMG 404) / Amgen, etevritamab (AMG 596) / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov) - Dec 3, 2019
P1, N=82, Recruiting,
N=82 --> 200 | Trial primary completion date: Aug 2024 --> Feb 2024 Trial completion date: Jun 2022 --> Aug 2024 | Trial primary completion date: Jun 2022 --> Aug 2024
- |||||||||| zeluvalimab (AMG 404) / Amgen, etevritamab (AMG 596) / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov) - Aug 14, 2019
P1, N=82, Recruiting,
NCT03296696. Trial completion date: Apr 2021 --> Jun 2022 | Trial primary completion date: Apr 2021 --> Jun 2022
- |||||||||| zeluvalimab (AMG 404) / Amgen, etevritamab (AMG 596) / Amgen
Trial initiation date, Combination therapy, Monotherapy: Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma (clinicaltrials.gov) - Mar 3, 2018
P1, N=82, Recruiting,
Trial completion date: Apr 2021 --> Jun 2022 | Trial primary completion date: Apr 2021 --> Jun 2022 Initiation date: Feb 2018 --> Mar 2018
|
